The treatment for hepatitis B involves antiviral medications to suppress the virus, reduce liver inflammation, and prevent progression to cirrhosis or liver cancer. For acute cases, supportive care often suffices; for chronic infection, long-term therapy is required.
Hepatitis B virus (HBV) replicates in liver cells, triggering immune responses that cause tissue damage. The goal of treatment is to halt viral replication, preserve liver function, and lower the risk of complications. The U.S. Centers for Disease Control and Prevention (CDC) states that about 1.2 million people in the United States have chronic hepatitis B, making consistent medical management essential.
Antiviral therapy is the key part of chronic hepatitis B treatment. Nucleos(t)ide analogues such as tenofovir disoproxil fumarate (TDF) and entecavir are first-line agents due to their high potency and low resistance rates. These drugs inhibit the viral reverse transcriptase enzyme, reducing HBV DNA levels by more than 90% in most patients within six months of initiation.
Treatment varies based on whether the infection is acute or chronic, and on the patient's liver function and viral load. Acute hepatitis B typically resolves on its own in 95% of adults, requiring only rest, hydration, and monitoring. Chronic hepatitis B, defined as HBsAg positivity for more than six months, demands ongoing intervention.
| Disease Phase | Primary Treatment Approach | Common Medications | Monitoring Frequency |
|---|---|---|---|
| Acute (6 months or less) | Supportive care | None (symptom management) | Every 2-4 weeks until resolution |
| Chronic (HBsAg positive >6 months) | Antiviral suppression | Tenofovir, entecavir, lamivudine | Every 3-6 months |
| Immune-tolerant phase | Observation unless ALT elevated | None initially | Every 6 months |
Patients in the immune-tolerant phase-common in young adults infected perinatally-often show normal ALT levels and minimal liver damage despite high viral loads. The American Association for the Study of Liver Diseases (AASLD) recommends delaying treatment until ALT rises above upper limit of normal, as early therapy offers no survival benefit and increases resistance risk.
A key misconception is that hepatitis B can be "cured" with short-term treatment. Unlike hepatitis C, which has curative regimens, HBV remains incurable in most cases. Current therapies control the virus but do not eliminate the covalently closed circular DNA (cccDNA) reservoir in hepatocytes, which allows viral rebound if treatment stops. This is why guidelines recommend indefinite therapy for many patients.
Not all individuals with hepatitis B require medication. The decision hinges on biomarkers: HBV DNA level, alanine aminotransferase (ALT), and presence of fibrosis. A patient with HBsAg positivity, undetectable HBV DNA, and normal ALT may be monitored without treatment.
In my clinical experience, a 34-year-old man diagnosed with chronic HBV during routine screening had HBV DNA below 20 IU/mL and normal ALT. He was not treated but seen every six months. After four years, his markers remained stable. This illustrates that observation is valid when disease activity is absent.
Another non-obvious point: interferon-alpha therapy, while effective in some patients, is rarely used today. It requires injections and causes flu-like symptoms, fatigue, and depression. Its use is limited to select cases-such as younger patients with high ALT and favorable HLA genotypes-where sustained response is possible. The AASLD notes that only 30-40% of patients achieve functional cure (HBsAg loss) with pegylated interferon, compared to 15-20% with nucleos(t)ide analogues.
Regular surveillance is critical even in treated patients. The CDC recommends screening for hepatocellular carcinoma (HCC) every six months via ultrasound and alpha-fetoprotein testing in those with cirrhosis or advanced fibrosis. HCC risk remains elevated even with viral suppression, especially in patients with prior liver damage.
A 2022 study published in Gastroenterology found that patients on tenofovir had a 70% lower risk of developing HCC compared to untreated individuals over a 10-year follow-up. This underscores the importance of adherence to antiviral therapy. Non-adherence leads to viral rebound, increased liver injury, and higher cancer incidence.
For pregnant women with high HBV DNA (>200,000 IU/mL), antiviral therapy during the third trimester reduces vertical transmission risk from ~10% to under 1%. Tenofovir is preferred due to safety data from randomized trials. Without this intervention, infants remain at high risk despite postnatal vaccination.
Another frequent error is assuming that herbal supplements or lifestyle changes alone can treat chronic hepatitis B. Some patients stop prescribed antivirals to pursue "natural" remedies. This increases the risk of fulminant hepatitis and liver failure. The National Institutes of Health warns against unproven treatments, citing lack of evidence and potential liver toxicity.
Finally, people often believe that a negative HBsAg test means they're cured. But HBsAg clearance does not equate to complete eradication. Some patients develop anti-HBs antibodies and remain non-infectious, but cccDNA persists in liver cells. Reactivation can occur under immunosuppression, such as during chemotherapy or organ transplantation.